Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-04-24Clinical Trial Update: Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration [Phase 2]
Phase 2 trial evaluating photodynamic therapy with bevacizumab versus bevacizumab alone for Neovascular age-related macular degeneration has…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
A clinical trial investigating aflibercept 8 mg for neovascular age-related macular degeneration and diabetic macular edema in real-world se…
-
CLINICAL_TRIALS withdrawal · 2024-05-30Clinical Trial Update: Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration [Phase 2]
Phase 2 trial evaluating bevacizumab in combination with photodynamic therapy for neovascular age-related macular degeneration was terminate…
-
CLINICAL_TRIALS withdrawal · 2024-01-18Clinical Trial Update: A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration [Phase 3]
A Phase 3 trial comparing a 36-week refill regimen of the Port Delivery System with ranibizumab versus aflibercept treat-and-extend in neova…
-
CLINICAL_TRIALS withdrawal · 2017-07-26Clinical Trial Update: Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD [NA]
A clinical trial investigating adjunctive photodynamic therapy with aflibercept for neovascular age-related macular degeneration has been wi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2017-04-27Clinical Trial Update: Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration [Phase 2]
Phase 2 trial of squalamine lactate ophthalmic solution (0.2%) for neovascular age-related macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-03-31Clinical Trial Update: Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration [Phase 1]
A Phase 1 trial evaluating pharmacokinetics, safety, and tolerability of BCD-021 in patients with neovascular age-related macular degenerati…
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
The document notes a trial evaluating pegaptanib sodium (Macugen) for neovascular age-related macular degeneration in Filipino patients, foc…
-
CLINICAL_TRIALS withdrawal · 2012-08-22Clinical Trial Update: Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD [Phase 1]
A Phase 1 safety and preliminary efficacy trial of PDS-1.0 for neovascular age-related macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2010-02-09Clinical Trial Update: Combination Therapy for Neovascular Age Related Macular Degeneration [NA]
A Yonsei University-sponsored clinical trial investigating a combination therapy for neovascular age-related macular degeneration has been w…